The Burden of Peripheral Artery Disease and the Role of Antiplatelet Therapy

References

• . Bhatt DL, Steg PG, Ohman EM, . International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295(2):180–189
   PubMed Web of Science ®Google Scholar
• . Steg PG, Bhatt DL, Wilson PW, . One-year cardiovascular event rates in outpatients with atherothrombosis. JAMA. 2007;297(11): 1197–1206
   PubMed Web of Science ®Google Scholar
• . Ostchega Y, Paulose-Ram R, Dillon CF, Gu Q, Hughes JP. Prevalence of peripheral arterial disease and risk factors in persons aged 60 and older: data from the National Health and Nutrition Examination Survey 1999-2004. J Am Geriatr Soc. 2007;55(4):583–589
   PubMed Web of Science ®Google Scholar
• . Criqui MH, Fronek A, Barrett-Connor E, Klauber MR, Gabriel S, Goodman D. The prevalence of peripheral arterial disease in a defined population. Circulation. 1985;71(3):510–515
   PubMed Web of Science ®Google Scholar
• . Stoffers HE, Rinkens PE, Kester AD, Kaiser V, Knottnerus JA. The prevalence of asymptomatic and unrecognized peripheral arterial occlusive disease. Int J Epidemiol. 1996;25(2):282–290
   PubMedGoogle Scholar
• . Aronow WS, Ahn C, Gutstein H. Prevalence and incidence of cardiovascular disease in 1160 older men and 2464 older women in a long-term health care facility. J Gerontol A Biol Sci Med Sci. 2002;57(1):M45–M46
   PubMed Web of Science ®Google Scholar
• . Ness J, Aronow WS, Ahn C. Risk factors for symptomatic peripheral arterial disease in older persons in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 2000;48(3):312–314
   PubMed Web of Science ®Google Scholar
• . Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial disease in the United States: results from the National Health and Nutrition Examination Survey, 1999-2000. Circulation. 2004;110(6):738–743
   PubMed Web of Science ®Google Scholar
• . Hirsch AT, Haskal ZJ, Hertzer NR, . ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation. 2006;113(11):e463–e654
   PubMed Web of Science ®Google Scholar
• . Scottish Intercollegiate Guidelines Network. Diagnosis and management of peripheral arterial disease: a national clinical guideline. Edinburgh, Scotland: SIGN; 2006
   Google Scholar
• . Dumville JC, Lee AJ, Smith FB, Fowkes FG. The health-related quality of life of people with peripheral arterial disease in the community: the Edinburgh Artery Study. Br J Gen Pract. 2004;54(508):826–831
   PubMedGoogle Scholar
• . Collins TC, Suarez-Almazor M, Bush RL, Petersen NJ. Gender and peripheral arterial disease. J Am Board Fam Med. 2006;19(2):132–140
   PubMedGoogle Scholar
• . Ness J, Aronow WS. Prevalence of coexistence of coronary artery disease, ischemic stroke, and peripheral arterial disease in older persons, mean age 80 years, in an academic hospital-based geriatrics practice. J Am Geriatr Soc. 1999;47(10):1255–1256
   PubMedGoogle Scholar
• . Fowkes FG, Low LP, Tuta S, Kozak J; AGATHA Investigators. Ankle brachial index and extent of atherothrombosis in 8891 patients with or at risk of vascular disease: results of the international AGATHA study. Eur Heart J. 2006;27(15):1861–1867
   PubMedGoogle Scholar
• . American Cancer Society. Cancer facts and figures 2007. Atlanta, GA: American Cancer Society; 2007
   Google Scholar
• . Leng GC, Lee AJ, Fowkes FG, . Incidence, natural history and cardiovascular events in symptomatic and asymptomatic peripheral arterial disease in the general population. Int J Epidemiol. 1996;25(6):1172–1181
   PubMed Web of Science ®Google Scholar
• . Criqui MH, Langer RD, Fronek A, . Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med. 1992;326(6):381–386
   PubMed Web of Science ®Google Scholar
• . Jaff MR. Peripheral arterial disease costlier to treat than coronary artery disease. International Symposium on Endovascular Therapy, Hollywood, FL; 2008
   Google Scholar
• . Hirsch AT, Hartman L, Town RJ, Virnig BA. National health care costs of peripheral arterial disease in the Medicare population. Vasc Med. 2008;13(3):209–215
   PubMedGoogle Scholar
• . The SAGE Group. Peripheral Arterial Disease (PAD)-related amputations cost an estimated $10 billion. http://thesagegroup.us/press%20releases/amputation%20sept04.html. Accessed July 1, 2009
   Google Scholar
• . Hirsch AT, Murphy TP, Lovell MB, . Gaps in public knowledge of peripheral arterial disease: the first national PAD public awareness survey. Circulation. 2007;116(18):2086–2094
   PubMed Web of Science ®Google Scholar
• . Hirsch AT, Criqui MH, Treat-Jacobson D, . Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286(11):1317–1324
   PubMed Web of Science ®Google Scholar
• . Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg. 2000;31(1 pt 2):S1–S296
   PubMedGoogle Scholar
• . Leng GC, Fowkes FG. The Edinburgh Claudication Questionnaire: an improved version of the WHO/Rose Questionnaire for use in epidemiological surveys. J Clin Epidemiol. 1992;45(10):1101–1109
   PubMedGoogle Scholar
• . Regensteiner JG, Steiner JF, Panzer RJ, Hiatt WR. Evaulation of walking impairment by questionnaire in patients with peripheral arterial disease. J Vasc Med Biol. 1990;2:142–152
   Google Scholar
• . Spertus J, Jones P, Poler S, Rocha-Singh K. The peripheral artery questionnaire: a new disease-specific health status measure for patients with peripheral arterial disease. Am Heart J. 2004;147(2):301–308
   PubMed Web of Science ®Google Scholar
• . Norgren L, Hiatt WR, Dormandy JA, . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Eur J Vasc Endovasc Surg. 2007;33( suppl 1):S1–S75
   PubMed Web of Science ®Google Scholar
• . Sikkink CJ, van Asten WN, van't Hof MA, van Langen H, van der Vliet JA. Decreased ankle/brachial indices in relation to morbidity and mortality in patients with peripheral arterial disease. Vasc Med. 1997;2(3):169–173
   PubMedGoogle Scholar
• . Newman AB, Siscovick DS, Manolio TA, . Ankle-arm index as a marker of atherosclerosis in the Cardiovascular Health Study. Cardiovascular Heart Study (CHS) Collaborative Research Group. Circulation. 1993;88(3):837–845
   PubMed Web of Science ®Google Scholar
• . Fowkes FG, Murray GD, Butcher I, . Ankle brachial index combined with Framingham Risk Score to predict cardiovascular events and mortality: a meta-analysis. JAMA. 2008;300(2):197–208
   PubMed Web of Science ®Google Scholar
• . He Y, Jiang Y, Wang J, Fan L, Li X, Hu FB. Prevalence of peripheral arterial disease and its association with smoking in a population-based study in Beijing, China. J Vasc Surg. 2006;44(2):333–338
   PubMed Web of Science ®Google Scholar
• . Aboyans V, Criqui MH, Denenberg JO, Knoke JD, Ridker PM, Fronek A. Risk factors for progression of peripheral arterial disease in large and small vessels. Circulation. 2006;113(22):2623–2629
   PubMed Web of Science ®Google Scholar
• . Willigendael EM, Teijink JA, Bartelink ML, Peters RJ, Buller HR, Prins MH. Smoking and the patency of lower extremity bypass grafts: a meta-analysis. J Vasc Surg. 2005;42(1):67–74
   PubMed Web of Science ®Google Scholar
• . Tapp RJ, Balkau B, Shaw JE, Valensi P, Cailleau M, Eschwege E. Association of glucose metabolism, smoking and cardiovascular risk factors with incident peripheral arterial disease: the DESIR study. Atherosclerosis. 2007;190(1):84–89
   PubMedGoogle Scholar
• . Leibson CL, Ransom JE, Olson W, Zimmerman BR, O'Fallon WM, Palumbo PJ. Peripheral arterial disease, diabetes, and mortality. Diabetes Care. 2004;27(12):2843–2849
   PubMedGoogle Scholar
• . Kallio M, Forsblom C, Groop PH, Groop L, Lepantalo M. Development of new peripheral arterial occlusive disease in patients with type 2 diabetes during a mean follow-up of 11 years. Diabetes Care. 2003;26(4):1241–1245
   PubMedGoogle Scholar
• . Wattanakit K, Folsom AR, Selvin E, . Risk factors for peripheral arterial disease incidence in persons with diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis. 2005;180(2):389–397
   PubMedGoogle Scholar
• . Khattab AD, Ali IS, Rawlings B. Peripheral arterial disease in diabetic patients selected from a primary care setting: implications for nursing practice. J Vasc Nurs. 2005;23(4):139–148
   PubMedGoogle Scholar
• . Carmona GA, Hoffmeyer P, Herrmann FR, . Major lower limb amputations in the elderly observed over ten years: the role of diabetes and peripheral arterial disease. Diabetes Metab. 2005;31(5):449–454
   PubMedGoogle Scholar
• . Malmstedt J, Wahlberg E, Jörneskog G, Swedenborg J. Influence of perioperative blood glucose levels on outcome after infrainguinal bypass surgery in patients with diabetes. Br J Surg. 2006;93(11):1360–1367
   PubMedGoogle Scholar
• . Wattanakit K, Folsom AR, Selvin E, Coresh J, Hirsch AT, Weatherley BD. Kidney function and risk of peripheral arterial disease: results from the Atherosclerosis Risk in Communities (ARIC) Study. J Am Soc Nephrol. 2007;18(2):629–636
   PubMed Web of Science ®Google Scholar
• . Owens CD, Ho KJ, Kim S, . Refinement of survival prediction in patients undergoing lower extremity bypass surgery: stratification by chronic kidney disease classification. J Vasc Surg. 2007;45(5):944–952
   PubMedGoogle Scholar
• . O'Hare AM, Bertenthal D, Shlipak MG, Sen S, Chren MM. Impact of renal insufficiency on mortality in advanced lower extremity peripheral arterial disease. J Am Soc Nephrol. 2005;16(2):514–519
   PubMedGoogle Scholar
• . Lange S, Trampisch HJ, Haberl R, . Excess 1-year cardiovascular risk in elderly primary care patients with a low ankle-brachial index (ABI) and high homocysteine level. Atherosclerosis. 2005;178(2): 351–357
   PubMedGoogle Scholar
• . Taute BM, Taute R, Heins S, Behrmann C, Podhaisky H. Hyperhomo cysteinemia: marker of systemic atherosclerosis in peripheral arterial disease. Int Angiol. 2004;23(1):35–10
   PubMedGoogle Scholar
• . Taylor LM Jr, Moneta GL, Sexton GJ, Schuff RA, Porter JM. Prospective blinded study of the relationship between plasma homocysteine and progression of symptomatic peripheral arterial disease. J Vasc Surg. 1999;29(1):8–19
   PubMedGoogle Scholar
• . Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation. 1998;97(5):425–428
   PubMed Web of Science ®Google Scholar
• . Allison MA, Criqui MH, McClelland RL, . The effect of novel cardiovascular risk factors on the ethnic-specific odds for peripheral arterial disease in the Multi-Ethnic Study of Atherosclerosis (MESA). J Am Coll Cardiol. 2006;48(6):1190–1197
   PubMed Web of Science ®Google Scholar
• . Vu JD, Vu JB, Pio JR, . Impact of C-reactive protein on the likelihood of peripheral arterial disease in United States adults with the metabolic syndrome, diabetes mellitus, and preexisting cardiovascular disease. Am J Cardiol. 2005;96(5):655–658
   PubMedGoogle Scholar
• . Tzoulaki I, Murray GD, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Inflammatory, haemostatic, and rheological markers for incident peripheral arterial disease: Edinburgh Artery Study. Eur Heart J. 2007;28(3):354–362
   PubMed Web of Science ®Google Scholar
• . Wildman RP, Muntner P, Chen J, Sutton-Tyrrell K, He J. Relation of inflammation to peripheral arterial disease in the national health and nutrition examination survey, 1999-2002. Am J Cardiol. 2005;96(11):1579–1583
   PubMedGoogle Scholar
• . Vainas T, Stassen FR, de Graaf R, . C-reactive protein in peripheral arterial disease: relation to severity of the disease and to future cardiovascular events. J Vasc Surg. 2005;42(2):243–251
   PubMedGoogle Scholar
• . McDermott MM, Ferrucci L, Liu K, . D-dimer and inflammatory markers as predictors of functional decline in men and women with and without peripheral arterial disease. J Am Geriatr Soc. 2005;53(10):1688–1696
   PubMedGoogle Scholar
• . Engström G, Site-Flondell D, Lindblad B, Janzon L, Lindgärde F. Risk of treatment of peripheral arterial disease is related to inflammation-sensitive plasma proteins: a prospective cohort study. J Vasc Surg. 2004;40(6):1101–1105
   PubMedGoogle Scholar
• . Doweik L, Maca T, Schillinger M, Budinsky A, Sabeti S, Minar E. Fibrinogen predicts mortality in high risk patients with peripheral artery disease. Eur J Vasc Endovasc Surg. 2003;26(4):381–386
   PubMed Web of Science ®Google Scholar
• . Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet. 2002;360(9326):7–22
   PubMed Web of Science ®Google Scholar
• . Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Arch Intern Med. 1991;151(9):1769–1776
   PubMedGoogle Scholar
• . Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G; The Heart Outcomes Prevention Evaluation Study Investigators. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. N Engl J Med. 2000;342(3):145–153
   PubMed Web of Science ®Google Scholar
• . Dluhy RG, McMahon GT. Intensive glycemic control in the ACCORD and ADVANCE trials. N Engl J Med. 2008;358(24):2630–2633
   PubMed Web of Science ®Google Scholar
• . Merchant AT, Hu FB, Spiegelman D, Willett WC, Rimm EB, Ascherio A. The use of B vitamin supplements and peripheral arterial disease risk in men are inversely related. J Nutr. 2003;133(9):2863–2867
   PubMed Web of Science ®Google Scholar
• . Carrero JJ, Lopez-Huertas E, Salmeron LM, Baro L, Ros E. Daily supplementation with (n-3) PUFAs, oleic acid, folic acid, and vitamins B-6 and E increases pain-free walking distance and improves risk factors in men with peripheral vascular disease. J Nutr. 2005;135(6):1393–1399
   PubMedGoogle Scholar
• . Schernthaner GH, Plank C, Minar E, Bieglmayer C, Koppensteiner R, Schernthaner G. No effect of homocysteine-lowering therapy on vascular inflammation and haemostasis in peripheral arterial occlusive disease. Eur J Clin Invest. 2006;36(5):333–339
   PubMedGoogle Scholar
• . CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348(9038):1329–1339
   PubMed Web of Science ®Google Scholar
• . Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71–86
   PubMed Web of Science ®Google Scholar
• . Berger JS, Krantz MJ, Kittelson JM, Hiatt WR. Aspirin for the prevention of cardiovascular events in patients with peripheral artery disease: a meta-analysis of randomized trials. JAMA. 2009;301(18):1909–1919
   PubMed Web of Science ®Google Scholar
• . Bhatt DL, Flather MD, Hacke W, . Patients with prior myocardial infarction, stroke, or symptomatic peripheral arterial disease in the CHARISMA trial. J Am Coll Cardiol. 2007;49(19):1982–1988
   PubMed Web of Science ®Google Scholar
• . Mukherjee D, Topol EJ, Moliterno DJ, . Extracardiac vascular disease and effectiveness of sustained clopidogrel treatment. Heart. 2006;92(1):49–51
   PubMedGoogle Scholar
• . Dorffler-Melly J, Koopman MM, Prins MH, Buller HR. Antiplatelet and anticoagulant drugs for prevention of restenosis/reocclusion following peripheral endovascular treatment. Cochrane Database Syst Rev. 2005;(1):CD002071
   Google Scholar
• . Park SW, Lee CW, Kim HS, . Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol. 2000;86(5):499–503
   PubMedGoogle Scholar
• . Kwon SU, Cho YJ, Koo JS, . Cilostazol prevents the progression of the symptomatic intracranial arterial stenosis: the multicenter double-blind placebo-controlled trial of cilostazol in symptomatic intracranial arterial stenosis. Stroke. 2005;36(4):782–786
   PubMed Web of Science ®Google Scholar
• . Anand SS, Yusuf S. Oral anticoagulants in patients with coronary artery disease. J Am Coll Cardiol. 2003;41( 4 suppl):62S–69S
   PubMed Web of Science ®Google Scholar
• . Mohler ER 3rd. Atherothrombosis—wave goodbye to combined anticoagulation and antiplatelet therapy? N Engl J Med. 2007;357(3):293–296
   PubMedGoogle Scholar
• . Stewart KJ, Hiatt WR, Regensteiner JG, Hirsch AT. Exercise training for claudication. N Engl J Med. 2002;347(24):1941–1951
   PubMedGoogle Scholar
• . de Vries SO, Visser K, de Vries JA, Wong JB, Donaldson MC, Hunink MG. Intermittent claudication: cost-effectiveness of revascularization versus exercise therapy. Radiology. 2002;222(1):25–36
   PubMedGoogle Scholar
• . Regensteiner JG, Ware JE Jr, McCarthy WJ, . Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc. 2002;50(12):1939–1946
   PubMed Web of Science ®Google Scholar
• . Thompson PD, Zimet R, Forbes WP, Zhang P. Metaanalysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol. 2002;90(12):1314–1319
   PubMedGoogle Scholar
• . Girolami B, Bernardi E, Prins MH, . Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med. 1999;159(4):337–345
   PubMedGoogle Scholar
• . Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ. 1996;155(8):1053–1059
   PubMedGoogle Scholar
• . Bianchi C, Montalvo V, Ou HW, Bishop V, Abou-Zamzam AM. Pharmacologic risk factor treatment of peripheral arterial disease is lacking and requires vascular surgeon participation. Ann Vasc Surg. 2007;21(2):163–166
   PubMedGoogle Scholar
• . Khan S, Flather M, Mister R, . Characteristics and treatments of patients with peripheral arterial disease referred to UK vascular clinics: results of a prospective registry. Eur J Vasc Endovasc Surg. 2007;33(4):442–450
   PubMedGoogle Scholar
• . Froehlich JB, Mukherjee D, Avezum A, . Association of peripheral artery disease with treatment and outcomes in acute coronary syndromes. The Global Registry of Acute Coronary Events (GRACE). Am Heart J. 2006;151:1123–1128
   PubMed Web of Science ®Google Scholar
• . Conte MS, Bandyk DF, Clowes AW, Moneta GL, Namini H, Seely L. Risk factors, medical therapies and perioperative events in limb salvage surgery: observations from the PREVENT III multicenter trial. J Vasc Surg. 2005;42(3):456–464
   PubMedGoogle Scholar
• . Bradley L, Kirker SG. Secondary prevention of arteriosclerosis in lower limb vascular amputees: a missed opportunity. Eur J Vasc Endovasc Surg. 2006;32(5):491–493
   PubMedGoogle Scholar
• . Hasimu B, Li J, Yu J, . Evaluation of medical treatment for peripheral arterial disease in Chinese high-risk patients. Circ J. 2007;71(1):95–99
   PubMedGoogle Scholar
• . Blacher J, Cacoub P, Luizy F, . Peripheral arterial disease versus other localizations of vascular disease: the ATTEST study. J Vasc Surg. 2006;44(2):314–318
   PubMedGoogle Scholar
• . Smaha LA. The American Heart Association Get With The Guidelines program. Am Heart J. 2004;148( 5 suppl):S46–S48
   PubMed Web of Science ®Google Scholar
• . Rehring TF, Stolcpart RS, Sandhoff BG, Merenich JA, Hollis HW. Effect of a clinical pharmacy service on lipid control in patients with peripheral arterial disease. J Vasc Surg. 2006;43(6):1205–1210
   PubMedGoogle Scholar
• . Mukherjee D, Munir K, Hirsch AT, . Development of a multicenter peripheral arterial interventional database: the PVD-QI2. Am Heart J. 2005;149(6):1003–1008
   PubMedGoogle Scholar
• . Criqui MH, Denenberg JO, Bird CE, Fronek A, Klauber MR, Langer RD. The correlation between symptoms and non-invasive test results in patients referred for peripheral arterial disease testing. Vasc Med. 1996;1(1):65–71
   PubMedGoogle Scholar